Valneva SE (VLA) said Monday that the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act or PDUFA action date for the Biologics License Application or BLA for the company's chikungunya virus vaccine candidate, VLA1553, from the previously communicated end of August to the end of November.
The PDUFA extension will allow sufficient time to align and agree on the phase 4 program necessary under the accelerated approval pathway. No additional clinical data have been requested for the approval process, the company said in a statement.
Valneva reconfirmed its previous guidance for potential BLA approval, initial launch, and potential award of a priority review voucher still in 2023. The PDUFA extension does not impact the company's current regulatory submission in Canada or its planned submission with the European Medicines Agency.
For More Such Health News, visit rttnews.com
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.